ReviewAmerican heart journal plus : cardiology research and practice2026
The role of soluble suppression of tumorigenicity 2 in pulmonary hypertension: a systematic review and meta-analysis.
Review in American heart journal plus : cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary hypertension (pH) is characterized by an increase in pulmonary vascular resistance. Although soluble suppression of tumorigenicity-2 (sST2) has been identified as a biomarker for heart failure, the implication of sST2 in PH has not been well studied. Objective: This study aimed to investigate the value of sST2 in predicting prognosis of PH and the correlation between sST2 and pulmonary arterial pressure (PAP). Methods: We conducted a systematic review of databases including PubMed and Embase. Levels of sST2 in the PH group and the control group were compared. Data on the accuracy of sST2 for predicting clinical worsening and Hazard ratios (HR) for the association of sST2 with poor outcomes were pooled. Additionally, correlation coefficients between sST2 levels and mean pulmonary arterial pressure (mPAP) and several other clinical parameters were pooled. Meta-regression and subgroup analysis was conducted to identify the source of heterogeneity. Results: 15 studies were included in our study. Levels of sST2 were significantly higher in PH group (641 subjects) than control group (575 subjects) (SMD 0.71, 95%CI 0.43-0.98, Conclusion: SST2 levels were elevated among patients with PH and correlated to PAP and right cardiac dysfunction. sST2 played a reliable role in predicting prognosis of PH despite the limitations and heterogeneity among the studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.